Transplantation for Patients With Chronic Lymphocytic Leukemia

Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00186303

Enrollment

Registered

2005-09-16

Start date

1996-11-30

Completion date

2010-03-31

Last updated

2012-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Lymphocytic, Chronic

Brief summary

To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.

Detailed description

To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic leukemia.

Interventions

PROCEDUREhigh dose chemotherapy then autologous hematopoietic cell transplant

PROCEDUREablative allogeneic hematopoietic cell transplant

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

- adequate organ function * normal bone marrow cytogenetics

Exclusion criteria

- active CNS disease * For autologous patients more than 30% bone marrow involvement

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
olymerase Chain Reaction (PCR) for minimal residual disease	—
Feasibility	—
Toxicity	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026